Chironi Gilles, Simon Alain, Gariepy Jérome, Balice Maria, Del-Pino Muriel, Levenson Jaime
Centre de Médecine Préventive Cardiovasculaire, Hôpital Broussais-Assistance Publique-Hôpitaux de Paris and Faculté de Médecine Paris 5, Paris, France.
Am J Hypertens. 2005 Nov;18(11):1476-81. doi: 10.1016/j.amjhyper.2005.05.019.
The effects of statins on intima-media thickness (IMT) are well documented, whereas those of fibrates are unknown. Therefore we compared IMT under treatment with each class of drugs.
We studied a cohort of consecutive dyslipidemic subjects treated with statin (n = 291) or fibrate (n = 82) drugs. Fibrate-treated subjects were matched with the same number of statin-treated subjects to obtain two subgroups of similar demographic and risk factors including LDL cholesterol. Common carotid far wall IMT and lumen diameter were measured by ultrasonography.
In the entire study population, IMT was greater in the fibrate group than in the statin group (P < .001), even after adjustment for LDL cholesterol and other covariates (P < .05). In the matched groups, IMT was greater in fibrate group than in the statin group (P < .01), even after adjustment for LDL cholesterol and other covariates including treatment duration (P < .01). The IMT correlated positively with treatment duration in the fibrate group (P < 0.05) but not in the statin group. In addition, IMT correlated positively with carotid lumen diameter in both the fibrate and statin groups (P < .05, P < .01) but with a lower slope in the former (P < .05).
In this study fibrate treatment was associated with greater IMT, steeper IMT-time relationship, and lower compensatory carotid enlargement than was statin treatment. These differences were not explained by differences in LDL cholesterol.
他汀类药物对内膜中层厚度(IMT)的影响已有充分文献记载,而贝特类药物的影响尚不清楚。因此,我们比较了使用这两类药物治疗时的IMT。
我们研究了一组连续的血脂异常受试者,他们分别接受他汀类药物治疗(n = 291)或贝特类药物治疗(n = 82)。将接受贝特类药物治疗的受试者与相同数量的接受他汀类药物治疗的受试者进行匹配,以获得两个具有相似人口统计学和风险因素(包括低密度脂蛋白胆固醇)的亚组。通过超声测量颈总动脉远壁的IMT和管腔直径。
在整个研究人群中,即使在调整了低密度脂蛋白胆固醇和其他协变量后,贝特类药物组的IMT仍高于他汀类药物组(P <.001)(P <.05)。在匹配组中,即使在调整了低密度脂蛋白胆固醇和包括治疗持续时间在内的其他协变量后,贝特类药物组的IMT仍高于他汀类药物组(P <.01)(P <.01)。在贝特类药物组中,IMT与治疗持续时间呈正相关(P < 0.05),而在他汀类药物组中则无此相关性。此外,在贝特类药物组和他汀类药物组中,IMT均与颈动脉管腔直径呈正相关(P <.05,P <.01),但前者的斜率较低(P <.05)。
在本研究中,与他汀类药物治疗相比,贝特类药物治疗与更大的IMT、更陡峭的IMT-时间关系以及更低的颈动脉代偿性扩张相关。这些差异不能用低密度脂蛋白胆固醇的差异来解释。